The Scientific World Journal

The Scientific World Journal / 2006 / Article

Mini-Review Article | Open Access

Volume 6 |Article ID 216841 |

Koji Kawakami, Oumi Nakajima, Ryuichi Morishita, Ryozo Nagai, "Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties", The Scientific World Journal, vol. 6, Article ID 216841, 10 pages, 2006.

Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties

Academic Editor: Frank S. Walsh
Received28 Jan 2006
Revised04 May 2006
Accepted27 Jun 2006


Despite the progress of the bioinformatics approach to characterize cell-surface antigens and receptors on tumor cells, it remains difficult to generate novel cancer vaccines or neutralizing monoclonal antibody therapeutics. Among targeted cancer therapeutics, biologicals with targetable antibodies or ligands conjugated or fused to toxins or chemicals for direct cell-killing ability have been developed over the last 2 decades. These conjugated or fused chimeric proteins are termed immunotoxins or cytotoxic agents. Two agents, DAB389IL-2 (ONTAKTM) targeting the interleukin-2 receptor and CD33-calicheamicin (Mylotarg®), have been approved by the FDA for cutaneous T-cell lymphoma (CTCL) and relapsed acute myeloid leukemia (AML), respectively. Such targetable agents, including RFB4(dsFv)-PE38 (BL22), IL13-PE38QQR, and Tf-CRM107, are being tested in clinical trials. Several agents using unique technology such as a cleavable adapter or immunoliposomes with antibodies are also in the preclinical stage. This review summarizes the generation, mechanism, and development of these agents. In addition, possible future directions of this therapeutic approach are discussed.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.